References
1 Toorop, M. M. A., Chen, Q., Tichelaar, V., Cannegieter, S. C. &
Lijfering, W. M. Predictors, time course, and outcomes of persistence
patterns in oral anticoagulation for non-valvular atrial fibrillation: a
Dutch Nationwide Cohort Study. Eur Heart J 42 ,
4126-4137, doi:10.1093/eurheartj/ehab421 (2021).
2 Escobar, C. et al. Effectiveness and Safety of Dabigatran
Compared to Vitamin K Antagonists in Non-Asian Patients with Atrial
Fibrillation: A Systematic Review and Meta-Analysis. Clin Drug
Investig 41 , 941-953, doi:10.1007/s40261-021-01091-w (2021).
3 Chen, S. T. & Patel, M. R. Comparison of Anticoagulant Therapy for
Atrial Fibrillation - Novel Oral Anticoagulants Versus Vitamin K
Antagonists. Prog Cardiovasc Dis 60 , 514-523,
doi:10.1016/j.pcad.2018.01.005 (2018).
4 Lip, G. Y. H. et al. Oral anticoagulants for nonvalvular atrial
fibrillation in frail elderly patients: insights from the ARISTOPHANES
study. J Intern Med 289 , 42-52, doi:10.1111/joim.13140
(2021).
5 Gu, Z. C. et al. Left Atrial Appendage Thrombus Formation in a
Patient on Dabigatran Therapy Associated With ABCB1 and CES-1 Genetic
Defect. Front Pharmacol 9 , 491,
doi:10.3389/fphar.2018.00491 (2018).
6 Ji, Q. et al. The impact of ABCB1 and CES1 polymorphisms on
dabigatran pharmacokinetics and pharmacodynamics in patients with atrial
fibrillation. Br J Clin Pharmacol 87 , 2247-2255,
doi:10.1111/bcp.14646 (2021).
7 Pare, G. et al. Genetic determinants of dabigatran plasma
levels and their relation to bleeding. Circulation 127 ,
1404-1412, doi:10.1161/CIRCULATIONAHA.112.001233 (2013).
8 Shi, J. et al. Dabigatran etexilate activation is affected by
the CES1 genetic polymorphism G143E (rs71647871) and gender.Biochem Pharmacol 119 , 76-84,
doi:10.1016/j.bcp.2016.09.003 (2016).
9 Sychev, D. et al. Effect of CES1 and ABCB1 genotypes on the
pharmacokinetics and clinical outcomes of dabigatran etexilate in
patients with atrial fibrillation and chronic kidney disease. Drug
Metab Pers Ther 35 , doi:10.1515/dmpt-2019-0029 (2020).
10 Sychev, D. A. et al. Genetic determinants of dabigatran safety
(CES1 gene rs2244613 polymorphism) in the Russian population:
multi-ethnic analysis. Mol Biol Rep 46 , 2761-2769,
doi:10.1007/s11033-019-04722-w (2019).
11 Zubiaur, P. et al. Effect of Sex, Use of Pantoprazole and
Polymorphisms in SLC22A1, ABCB1, CES1, CYP3A5 and CYP2D6 on the
Pharmacokinetics and Safety of Dabigatran. Adv Ther 37 ,
3537-3550, doi:10.1007/s12325-020-01414-x (2020).
12 Liu, Y. et al. The Impact of ABCB1 and CES1 Polymorphisms on
Dabigatran Pharmacokinetics in Healthy Chinese Subjects.Pharmgenomics Pers Med 14 , 477-485,
doi:10.2147/PGPM.S291723 (2021).
13 Dimatteo, C. et al. Pharmacogenetics of dabigatran etexilate
interindividual variability. Thromb Res 144 , 1-5,
doi:10.1016/j.thromres.2016.05.025 (2016).
14 Zhu, Z. et al. Dabigatran plasma concentration indicated the
risk of patients with non-valvular atrial fibrillation. Heart
Vessels , doi:10.1007/s00380-021-01974-0 (2021).
15 Hori, M. et al. Dabigatran versus warfarin: effects on
ischemic and hemorrhagic strokes and bleeding in Asians and non-Asians
with atrial fibrillation. Stroke 44 , 1891-1896,
doi:10.1161/STROKEAHA.113.000990 (2013).
16 Raymond, J. et al. Pharmacogenetics of Direct Oral
Anticoagulants: A Systematic Review. J Pers Med 11 ,
doi:10.3390/jpm11010037 (2021).
17 Wu, T., Xia, X., Fu, J., Chen, W. & Zhang, J. Left atrial appendage
thrombus formation in a patient with atrial fibrillation on dabigatran
therapy associated with CES1 and ABCB1 genetic polymorphisms: A case
report. Medicine (Baltimore) 99 , e22084,
doi:10.1097/MD.0000000000022084 (2020).
18 Rosian, A. N. et al. An Exploratory Association Analysis of
ABCB1 rs1045642 and ABCB1 rs4148738 with Non-Major Bleeding Risk in
Atrial Fibrillation Patients Treated with Dabigatran or Apixaban.J Pers Med 10 , doi:10.3390/jpm10030133 (2020).
19 Sychev, D. A. et al. The impact of ABCB1 (rs1045642 and
rs4148738) and CES1 (rs2244613) gene polymorphisms on dabigatran
equilibrium peak concentration in patients after total knee
arthroplasty. Pharmgenomics Pers Med 11 , 127-137,
doi:10.2147/PGPM.S169277 (2018).
20 Lahteenmaki, J. et al. Pharmacogenetics of Bleeding and
Thromboembolic Events in Direct Oral Anticoagulant Users. Clin
Pharmacol Ther 110 , 768-776, doi:10.1002/cpt.2316 (2021).